Trial · NCT07479979
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT07479979, Phase 1, Phase 2, Recruiting, Natalie Callander
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Trials, record NCT07479979. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07479979
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
- NCT number
- NCT07479979
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 62 participants, estimated
- Lead sponsor
- Natalie Callander
- Conditions
- Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone
- First posted
- 2026-03-18
- Last updated
- 2026-08-31
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Adverse Events | 24 months | Adverse events will be assessed by evaluating Grade 3 and 4 toxicities as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. |
| Secondary | Progression-free Survival (PFS) | 24 months | PFS will be calculated from the date of start of study therapy to the date of progression based on International Myeloma Working Group (IMWG) criteria, or date of death due to any cause should progression not have occurred. |
| Secondary | Overall Response Rate (ORR) | 24 months | ORR will include confirmed stringent complete response (sCR), confirmed complete response (CR), confirmed very good partial response (VGPR), and confirmed partial response (PR), and will be determined as per IMWG criteria. |
| Secondary | Minimal Residual Disease (MRD) Rate | 24 months | MRD will be assessed by multiparametric flow cytometry and/or next-generation sequencing (NGS). |
| Secondary | Progression-free Survival (PFS) in subgroup population | 24 months | Comparison of PFS between patients previously exposed to anti-CD38 therapy and those naïve/exposed but not refractory to the combination of carfilzomib and daratumumab will be made by subgroup analysis. |
| Secondary | Overall Response Rate (ORR) in subgroup population | 24 months | Comparison of ORR between patients previously exposed to anti-CD38 therapy and those naïve/exposed but not refractory to the combination of carfilzomib and daratumumab will be made by subgroup analysis. |
| Secondary | Minimal Residual Disease (MRD) in subgroup population | 24 months | Comparison of MRD between patients previously exposed to anti-CD38 therapy and those naïve/exposed but not refractory to the combination of carfilzomib and daratumumab will be made by subgroup analysis. |
| Secondary | Quality of Life (QOL) | 24 months | Changes in quality of life, as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) 29 and Patient-Reported Outcome - Common Terminology Criteria for Adverse Events (PRO-CTCAE), administered at baseline, every other cycle of completed therapy, and at the 30-day safety follow up visit. PROMISE-29: Each question usually has five response options ranging in value from 1 (Not at All) to 5 (Very Much). Minimum score for the questionnaire is 28 and the maximum score is 150. The raw score is converted into a T-score. A higher PROMIS T-score represents more of the concept being measured. PRO-CTCAE: Responses are scored from 0 to 4 (or 0/1 for absent/present). The fields chosen are specific to this study. The minimum score for the questionnaire is 0 and the maximum score is 151. Respondents are also allowed to write in any additional symptoms and rate them from 0 to 4. At present there are no guidelines established for how to combine attributes into a single score. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07479979
GET https://conductscience.org/api/trials/v1/NCT07479979/registered